RxDoctor Payments Data

Suman Annambhotla, MD

Vascular Surgery · Gainesville, GANPI 1760712889

Payments from drug & device makers

What this record shows

The money is spread across several categories — travel and lodging (55.6%), food and beverage and speaking fees — rather than concentrated in one kind of arrangement. 44 manufacturers reported payments, led by Medtronic at 59.4% of the total. Reporting peaked in 2024 at $13,517 and has fallen 56.0% since, to $5,954 in 2025. Among vascular surgery clinicians in GA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$47,628in general payments, 2019–2025

Across 419 payments — averaging $113.67 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$28K
  • Inari Medical, Inc.$8K
  • Silk Road Medical, Inc.$4K
  • Penumbra, Inc.$3K
  • Shockwave Medical, Inc$1K
  • Abbott$793
  • plus $3K from 38 others
$938,654in research payments, 2019–2025

Across 355 payments — averaging $2644.10 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Inari Medical, Inc.$939K

What the payments were for

  • Speaking & faculty fees$5,60012%
  • Travel & lodging$26,49856%
  • Food & beverage$15,50033%
  • Education$300%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$47,628 in reported general payments places this provider in the 95th percentile of 176 vascular surgery providers in Georgia.

See all vascular surgery providers in Georgia

Medicare billing

Part B allowed, 2024
$164,658
Medicare patients
245
Services billed
747

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XareltoRivaroxaban24$17,140
ClopidogrelClopidogrel Bisulfate46$290
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen29$173
Tramadol Hcl20$21
Diazepam12$8

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonXarelto$280$17,14024 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 176 vascular surgery providers in Georgia.

Other vascular surgery in Gainesville

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →